secwatch.observer — SEC 8-K summary
======================================

Issuer:     Opus Genetics, Inc. (IRD)
CIK:        0001228627
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001140361-24-046028
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Opus Genetics reports Q3 net loss of $7.5M; pro forma cash $37M after Opus acquisition
--------------------------------------------------------------------------------

- Net loss $7.5M ($0.29/share) vs net income $5.6M in Q3 2023; revenue $3.9M down from $11.9M.
- Pro forma cash $37M post-merger with Opus Genetics; expects runway into 2026.
- Acquisition of Opus Genetics closed Oct 22; issued 5.2M common shares and 14,145 Series A preferred.
- Pipeline: four data readouts in 2025 including Phase 3 for Phentolamine in presbyopia and dim light.
- Gene therapy candidate OPGx-LCA5 showed visual improvement in 3/3 adult patients; pediatric enrollment Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1228627/000114036124046028/0001140361-24-046028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1228627/000114036124046028/ef20038443_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-046028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer